Drug-induced alveolitis associated with infliximab/azathioprine therapy;Medikamenten-induzierte alveolitis unter infliximab-/azathioprin-therapie

Pneumologie

Volumn 62, Issue 4, 2008, Pages 204-208

  El Hag, Karim ^a,c   Dercken, H G ^a   Prenzel, R ^a   Holzle E ^b  

^a PIUS HOSPITAL   (Germany)

^b KLINIKUM OLDENBURG   (Germany)

^c Department of Hematology and Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EFALIZUMAB; ETRETIN; FUMADERM; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

AGED; ANKYLOSING SPONDYLITIS; ARTICLE; ATOPIC DERMATITIS; BACTERIAL INFECTION; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; HUMAN; INFECTION RISK; LUNG ALVEOLITIS; MYCOSIS; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; VIRUS INFECTION; ALLERGIC PNEUMONITIS; CHEMICALLY INDUCED DISORDER; FEMALE; MIDDLE AGED; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ALVEOLITIS, EXTRINSIC ALLERGIC; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 42949113593     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1016443     Document Type: Article

References (16)

1. Garcia-Planella E, Domenech E, Esteve-Comas M et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF-α antibodies (infliximab). Eur J Gastroenterol Hepatol 2003; 15: 351-354
2. Berg PA. Risiken und Nebenwirkungsreaktionen unter einer Therapie mit TNF-α-Blockern. Eine immunologische Analyse. Dtsch Med Wochenschr 2004; 129: 1631-1634
3. Dotan I, Yeshurun D, Hallak A et al. Treatment of Crohn's disease with anti-TNF-α antibodies - the experience in the Tel Aviv Medical Center. Harefuah. 2001; 140: 289-293
4. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359: 1187-1193
5. Peno-Green L, Lluberas G, Kingsley T et al. Lung injury linked to etanercept therapy. Chest. 2002; 122: 1858-1860
6. Tengstrand B, Ernestam S, Engvall IL et al. TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports. Lakartidningen 2005; 102: 3788-3790
7. Allanore Y, Devos-Francois G, Caramella C et al. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006; 65: 834-835
8. Ostor AJ, Crisp AJ, Somerville MF et al. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004; 329: 1266
9. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006 Jun; 33 (6): 1189-1193. Epub 2006 Apr 15.
10. Kommentar in: J Rheumatol 2007 Jan ; 34 (1): 238-239 Autorenantwort 239
11. Foucher P, Biour M, Blayac JP et al. Drugs that may injure the respiratory system. Eur Respir J. 1997; 10: 265-279.
12. Kommentar in: Eur Respir J 1997; 10: 260-264
13. 7+CD4+ T-Lymphozyten in der bronchoalveolären Lavage als Marker für pulmonale Fibrosen, Beziehung zu interstitiellen Lungenkrankheiten und diagnostische Relevanz." Dissertationsschrift. Jena: Medizinische Fakultät der Friedrich-Schiller-Universität, 2004
14. Costabel U. Atlas der bronchoalveolären Lavage. Stuttgart: Thieme, 1993: 20-23
15. Yamane K, Ihn H, Asano Y et al. Antagonistic effects of TNF-α on TGF-beta signaling through down-regulation of TGF-β receptor type II in human dermal fibroblasts. J Immunol 2003; 171: 3855-3862
16. Chizzolini C, Parel Y, De Luca C et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003; 48: 2593-2604